Biotech Values

[DewDiligence]

DNA replies to Dow Jones’ query.
In the newswire update, instead of
saying that no one at Genentech was
available to comment on the NIH
announcement, it says the following:

>>
Genentech spokeswoman Dawn Kalmar said the company hasn't been formally approached with the [NIH] study proposal. She said the company is "concerned that a treatment is being used off-label," but it isn't planning on developing Avastin for eye treatment.

“We would rather look at funding studies that have the potential to meet other unmet medical needs, and looking where else Lucentis may be beneficial for patients, rather than redeveloping something that may or may not be better than what we already have,” Kalmar said.
<<

LOL